Maze Therapeutics to Participate in the 3rd Annual H.C. Wainwright BioConnect Investor Conference
Maze Therapeutics (MAZE), a clinical-stage biopharmaceutical company focused on developing small molecule precision medicines for renal, metabolic and cardiovascular diseases, has announced its participation in the upcoming 3rd Annual H.C. Wainwright BioConnect Investor Conference. CEO Jason Coloma, Ph.D., will deliver a company overview presentation on Tuesday, May 20, 2025, at 11 a.m. ET.
The presentation will be accessible through the Investors section of Maze's website at mazetx.com, with a replay available for 60 days. One-on-one meetings with management can be arranged through H.C. Wainwright representatives.
Maze Therapeutics (MAZE), un'azienda biofarmaceutica in fase clinica specializzata nello sviluppo di farmaci di precisione a piccole molecole per malattie renali, metaboliche e cardiovascolari, ha annunciato la sua partecipazione al 3° Annuale H.C. Wainwright BioConnect Investor Conference. Il CEO Jason Coloma, Ph.D., terrà una presentazione sull'azienda martedì 20 maggio 2025, alle 11:00 ET.
La presentazione sarà disponibile nella sezione Investitori del sito di Maze, mazetx.com, con una replica fruibile per 60 giorni. È possibile organizzare incontri individuali con il management tramite i rappresentanti di H.C. Wainwright.
Maze Therapeutics (MAZE), una compañía biofarmacéutica en etapa clínica enfocada en desarrollar medicamentos de precisión de moléculas pequeñas para enfermedades renales, metabólicas y cardiovasculares, ha anunciado su participación en la próxima 3ª Conferencia Anual de Inversores H.C. Wainwright BioConnect. El CEO Jason Coloma, Ph.D., realizará una presentación general de la empresa el martes 20 de mayo de 2025 a las 11 a.m. ET.
La presentación estará disponible en la sección de Inversores del sitio web de Maze, mazetx.com, con una repetición accesible durante 60 días. Se pueden concertar reuniones individuales con la dirección a través de los representantes de H.C. Wainwright.
Maze Therapeutics (MAZE)는 신장, 대사 및 심혈관 질환을 위한 소분자 정밀 의약품 개발에 중점을 둔 임상 단계의 바이오제약 회사로, 다가오는 제3회 연례 H.C. Wainwright BioConnect 투자자 컨퍼런스에 참여한다고 발표했습니다. CEO Jason Coloma 박사가 2025년 5월 20일 화요일 오전 11시(동부시간)에 회사 개요 발표를 진행할 예정입니다.
발표는 Maze 웹사이트의 투자자 섹션(mazetx.com)에서 시청할 수 있으며, 60일간 재시청이 가능합니다. 경영진과의 일대일 미팅은 H.C. Wainwright 담당자를 통해 조율할 수 있습니다.
Maze Therapeutics (MAZE), une société biopharmaceutique en phase clinique spécialisée dans le développement de médicaments de précision à petites molécules pour les maladies rénales, métaboliques et cardiovasculaires, a annoncé sa participation à la 3e conférence annuelle H.C. Wainwright BioConnect pour investisseurs. Le PDG Jason Coloma, Ph.D., présentera un aperçu de l'entreprise le mardi 20 mai 2025 à 11h00 ET.
La présentation sera accessible dans la section Investisseurs du site web de Maze, mazetx.com, avec un replay disponible pendant 60 jours. Des réunions individuelles avec la direction peuvent être organisées via les représentants de H.C. Wainwright.
Maze Therapeutics (MAZE), ein biopharmazeutisches Unternehmen in der klinischen Phase, das sich auf die Entwicklung von präzisen Kleinmolekül-Medikamenten für Nieren-, Stoffwechsel- und Herz-Kreislauf-Erkrankungen spezialisiert hat, hat seine Teilnahme an der bevorstehenden 3. jährlichen H.C. Wainwright BioConnect Investorenkonferenz bekanntgegeben. CEO Jason Coloma, Ph.D., wird am Dienstag, den 20. Mai 2025, um 11 Uhr ET eine Unternehmenspräsentation halten.
Die Präsentation ist im Investorenbereich der Maze-Website unter mazetx.com verfügbar, mit einer Wiedergabeoption für 60 Tage. Einzelgespräche mit dem Management können über die Vertreter von H.C. Wainwright arrangiert werden.
- None.
- None.
SOUTH SAN FRANCISCO, Calif., May 13, 2025 (GLOBE NEWSWIRE) -- Maze Therapeutics, Inc. (Nasdaq: MAZE), a clinical-stage biopharmaceutical company developing small molecule precision medicines for patients with renal, metabolic and cardiovascular diseases, today announced that Jason Coloma, Ph.D., chief executive officer of Maze Therapeutics, will present a company overview and participate in one-on-one meetings at the 3rd Annual H.C. Wainwright BioConnect Investor Conference on Tuesday, May 20, 2025.
The presentation will be held at 11 a.m. ET and will be available in the Investors section of the company's website at mazetx.com. A replay of the presentation will be archived for 60 days.
If you would like to request a one-on-one meeting with company management during the conference, please reach out to your H.C. Wainwright representative.
About Maze Therapeutics
Maze Therapeutics is a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small molecule precision medicines for patients living with renal, cardiovascular and related metabolic diseases, including obesity. The company is advancing a pipeline using its Compass platform, which provides insights into the genetic variants in disease and links them with the biological pathways that drive disease in specific patient groups. The company’s pipeline is led by two wholly owned lead programs, MZE829 and MZE782, each of which represents a novel precision medicine-based approach for patients. For more information, please visit mazetx.com, or follow us on LinkedIn and X.
IR/Corporate Contact:
Amy Bachrodt, Maze Therapeutics
abachrodt@mazetx.com
Media Contact:
Dan Budwick, 1AB
dan@1abmedia.com
FAQ
When is Maze Therapeutics (MAZE) presenting at the H.C. Wainwright BioConnect Conference 2025?
Who will be presenting for Maze Therapeutics at the H.C. Wainwright Conference?
How can investors access Maze Therapeutics' presentation at the H.C. Wainwright Conference?
What therapeutic areas does Maze Therapeutics (MAZE) focus on?
